HANCHORBIO INC. ANNOUNCES CLOSING OF SERIES-A FINANCING 漢康生技A輪融資交割圓滿完成

August 5th, 2022 – HanchorBio Inc. (“HanchorBio”), a biotechnology company pioneering the development of next-generation immunotherapies, today announced the successful completion of approximately US$20 million Series-A financing. The proceeds will enable HanchorBio to further expand and accelerate its growing pipeline of the proprietary Fc-based designer biologics (FBDB™) and to support the anticipated investigational new drug (IND)-enabling good laboratory practice (GLP) toxicology studies, IND submissions, and the first part of phase 1 clinical trials.

2022年8月5日,漢康生技——一家致力於成為開發下一代免疫療法先驅者的生物技術公司,宣佈成功完成了約計2000萬美金的A輪融資交割。本次A輪融資的資金將使漢康生技能夠進一步擴大和加速其不斷增長的專有“基於Fc設計的生物製藥(FBDB™)”管線研發進程,並將進一步支援擬申報新藥在臨床前研究階段(IND-enabling)的GLP毒理研究、新藥申報以及後續第一部分的臨床I期試驗。

HanchorBio’s Series A round is led by Sino Biopharmaceutical Limited (HK. 01177, “SBP”), a leading, innovative research and development driven pharmaceutical conglomerate in China, with a business scope that is vertically integrated including research and development, manufacturing and sales and marketing infrastructure. Other reputable institutional investors participating in this round include Yuexiu Industry Fund, Zero2ipo Group, Panacea Venture, YuanBio Venture Capital etc.

本次漢康生技的A輪融資由中國生物製藥有限公司(HK.01177,“中生製藥”)領投。中生製藥是中國領先的創新研究和研發驅動型醫藥集團,業務覆蓋醫藥研發平臺、智能化生產和強大銷售體系全產業鏈。本次A輪融資中其他知名的機構投資者還包括越秀產業基金、清科集團、Panacea Venture、元生創投等。

Founded in December 2020, HanchorBio is a global biotechnology company focusing on immuno-oncology. Based in Taipei, Shanghai, and San Francisco, HanchorBio is led by an experienced team of pharmaceutical industry veterans with proven track-record of success in biologics discovery and global development with bold vision to rewrite cancer therapies. Committed to reactivating the immune system to fight against diseases, the proprietary Fc-based designer biologics (FBDB™) platform enables unique biologics with diverse multi-targeting modalities to unleash both innate and adaptive immune systems to kill tumors. By making breakthroughs in multifunctional innovative molecular configurations in R&D and improving the methodologies and skillful process development in CMC, HanchorBio develops novel and transformative FBDBs™ to address unmet medical needs.

漢康生技是一家於2020年12月創立的專注於全球免疫腫瘤學的生物科技公司。創始團隊包括了在生物藥物科研和全球藥物開發方面擁有豐富經驗的科學家和管理人員,辦公地點分佈於台北、上海以及舊金山。公司和創始團隊大膽以譜寫腫瘤免疫療法新篇章為其願景,致力於重新啟動免疫系統以對抗疾病,專有“基於Fc設計的生物製藥(FBDB™)”平臺具有多種靶向模式的獨特生物製劑,能夠解鎖先天免疫系統和適應性免疫系統以殺死腫瘤。通過在研發過程中多功能創新分子構型上的突破、以及改進成分生產和控制(CMC)中產程開發的方法和路徑,漢康生技藉此以創新生物藥物FBDBs™來解決未被滿足的醫療需求。

“We are extremely pleased that Sino Biopharmaceutical Limited is leading our Series A round and welcome them, along with other elite investors, to HanchorBio. The supports and recognition of our investors and the selfless contribution of our team not only speak to the immense potential of our development portfolio of transformative immunotherapies but are also a reflection of our confidence in the expertise of HanchorBio,” said Scott Liu, Ph.D., Founder, Chairman and CEO at HanchorBio. “Under the stagnant global economic environment and capital market from the COVID pandemic during the first half of 2022, HanchorBio managed to execute efficiently and effectively the development of a robust pipeline. In addition, the team has generated over the past six months promising and exciting in-vivo data from multiple tumor animal models for multiple projects, which validated the potentials of the FBDB™ technology platform. Following this round of financing, HanchorBio continues to pursue its mission and vision , to become an admired biotech company that transforms innovative drug development with biologics having novel modalities.

“我們非常榮幸中生製藥作為領投方參與漢康生技本次A輪融資,同時我們也非常歡迎中生製藥以及其他業界享有盛譽的投資者一起加入漢康生技。投資者的支持和認可以及我們研發團隊的無私貢獻不僅證明了我們的變革性免疫療法開發具有巨大潛力,也反映了我們對自己的專業知識的信心”,漢康生技的創始人、董事長兼CEO劉世高博士表示,“在2022年上半年,受新冠肺炎疫情影響,全球經濟環境和資本市場停滯不前。儘管在這樣的情況下,漢康生技依然設法高效和有效地執行了健全的管線開發計畫。此外,我們的研發團隊在過去的六個月裡,從多個項目的多個腫瘤動物模型中產生了極具前景且令人興奮的胞內實驗資料(in-vivo data),這也驗證了FBDB™技術平臺的潛力。在本輪融資之後,漢康生技將繼續追求我們的使命和願景,藉由在多功能創新分子構型上的突破,提升創新生物藥研發的方法和路徑,成為備受景仰的開創型生物技術公司”。